Aminobenzoic acid and prospects of its use in ophthalmology practice

Abstract

Aminobenzoic acid is a biologically active substance widespread in nature, which has a wide range of therapeutic applications as an antiviral, antibacterial, antioxidant, antimutagenic, anticoagulant, fibrinolytic, immunomodulatory, radioprotective agent. As an interferon inducer it has been used for many years in mono- and complex therapy of viral eye lesions: conjunctivitis, keratoconjunctivitis, keratouveitis, including those caused by the herpes virus (Herpes simplex, Herpes zoster), adenoviruses; keratopathies of infectious, post-traumatic and postoperative origin. Taking into account the available information, a new drug has been registered and introduced into clinical practice, the main active ingredient of which is 0.007% aminobenzoic acid – Exinta. However, a number of studies have also shown the effectiveness of аminobenzoic acid in the treatment of neurodegenerative eye diseases by reducing the intensity of oxidative damage by lipid peroxidation products, as well as increasing the activity of transport adenosine triphosphatases in eye tissues. Based on the results obtained, it is recommended to use a 0.007% aminobenzoic acid solution not only for the treatment of viral eye diseases as an interferon inducer, but also in the treatment of uveitis, burns and eye injuries, retinal dystrophies, retinopathy, after ophthalmological operations, inflammatory and dystrophic diseases of the cornea, for keratopathies of various origins, for accommodation disorders, etc. In the given clinical example, 0.007% aminobenzoic acid showed its effectiveness in the lingering course of chronic conjunctivitis in the background of the low effectiveness of other drugs, where with the help of monotherapy it was possible to achieve clinical recovery.